Randomized trial · people

VIP (aviptadil): discharge at 7.8 vs 10 days in COVID-19

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In one small human trial, inhaled aviptadil added to standard care was well tolerated and tied to shorter hospital stays and better lung CT scores in COVID-19 patients.

Kind
Randomized trial
Studied in
People
Number studied
80
Published
2025
Journal
Med Princ Pract

What they tested

The team tested whether inhaled aviptadil, added to standard care, sped recovery in adults hospitalized with COVID-19.

How the study was done

A randomized, double-blind, placebo-controlled trial in 80 hospitalized adults with COVID-19 at 9 centers. Patients were split evenly between inhaled aviptadil and placebo (a dummy treatment), both on top of standard care, and the main measure was time to discharge within 30 days.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking VIP? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Average time to discharge was 7.8 days with aviptadil and 10 days with placebo (p = 0.049). On the modified Borg scale, a rating of how breathless patients felt, scores did not differ by group on day 3 but were lower with aviptadil on day 7 (p = 0.033). Lung damage scores on CT scans were similar on day 1, and improvement by day 28 was greater with aviptadil (p = 0.028). Deaths were 5.1% with aviptadil and 12.2% with placebo, and no patient dropped out because of side effects.

What it doesn’t show

This was a small trial of 80 patients, and the gap in time to discharge fell just under the usual cutoff for statistical significance. It covered only adults hospitalized with COVID-19 and followed them for about a month, so it shows nothing about other conditions or longer-term effects.

The paper

Esendagli et al. Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19. Med Princ Pract. 2025.

The compound

More studies on VIP

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking VIP? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo